Although it is widely believed that Hsp90 inhibitors induce cancer cell death through indirect down-regulation of survivin as one of its multiple therapeutic functions, a study demonstrated that 17-AAG treatment slightly increased the amount of survivin present in the human DU145 prostate cancer cells [7]. This evidence concerns the gene BIRC5 and prostate cancer.